Inhibitors that can block downstream or upstream elements in the EGFR signaling pathway have been extensively studied in cancer research over the past two decades with the reasons that EGFR downstream signaling regulates tumor progression via proliferation, angiogenesis, metastasis and drug resistance mechanisms [2, 8, 47–50]. The gene discussed is EGFR; the disease is cancer.